Advertisement

Topics

Pro-Trader Daily: Featured Company News - Cytokinetics Announces Positive Results for Phase-2 Clinical Trial of Omecamtiv Mecabril in Japanese Patients with Heart Failure

07:45 EDT 4 Aug 2017 | FinanzNachrichten

Research Desk Line-up: ImmunoGen Post Earnings Coverage LONDON, UK / ACCESSWIRE / August 4, 2017 / Pro-Trader Daily takes a look at the latest corporate events and news making the headlines for Cyt...

Original Article: Pro-Trader Daily: Featured Company News - Cytokinetics Announces Positive Results for Phase-2 Clinical Trial of Omecamtiv Mecabril in Japanese Patients with Heart Failure

NEXT ARTICLE

More From BioPortfolio on "Pro-Trader Daily: Featured Company News - Cytokinetics Announces Positive Results for Phase-2 Clinical Trial of Omecamtiv Mecabril in Japanese Patients with Heart Failure"

Quick Search
Advertisement